Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 1998
Industry: Medical Devices (Cardiovascular and Diagnostic)
Headquarters: South Jordan, Utah
Merit Medical Systems designs, manufactures, and markets single-use medical products primarily for the diagnosis and treatment of cardiovascular disease. The company focuses on angiography, angioplasty, and related interventional procedures. Its product portfolio includes inflation devices, control syringes, catheters, guidewires, and custom kits. In 1998, the company expanded its offerings to include wound irrigation devices and thrombolytic infusion catheters.
Key Financial Metrics
Note: Specific revenue, profit, cash flow, and balance sheet totals are incorporated by reference to the Annual Report to Shareholders (Exhibit 13.1) and are not explicitly stated in the text of this Form 10-K. The following metrics are derived from the text provided:
- Research and Development (R&D) Expenses: $3,244,477 for 1998 (down from $4,446,795 in 1997).
- Patent Royalties: $450,000 paid in 1998 (consistent with 1997 and 1996).
- Market Capitalization (Non-Affiliates): Approximately $32,156,930 as of March 26, 1999.
- Shares Outstanding: 7,508,914 as of March 26, 1999.
- Employee Count: 956 employees as of March 23, 1999 (760 in manufacturing, 90 in sales/marketing, 52 in R&D, 54 in administration).
- Facility Costs: Principal facility lease payments are approximately $108,000 per month; Ireland facility lease is approximately $135,000 per year (net of 40% subsidy).
Material Changes and Operational Highlights
- Product Expansion: Launched new product lines in 1998, including the "Fountain" infusion catheter, "Tomcat" PTCA guidewire, and "Squirt" wound irrigation system. Sales for Fountain and Tomcat began in the second quarter of 1998.
- International Growth: International sales grew by 11% in 1998, accounting for approximately 22% of total sales. The company established an international sales office in Maastricht, The Netherlands.
- Manufacturing Consolidation: Closed a 32,000 square foot facility in Saratoga Springs, New York, in September 1998. Operations were transferred to Salt Lake City (needles/catheters) and Galway, Ireland (guidewires). Added 25,000 square feet of manufacturing space in Murray, Utah.
- Asset Disposition: Sold approximately 1.5 acres of land and a 25,000 square foot building in Castlerea, Ireland, during 1998.
- Customer Concentration: No single customer accounted for more than 5.1% of total sales in 1998. OEM sales represented 3.4% of total revenue.
Guidance, Outlook, and Risks
Outlook and Strategy: The company anticipates R&D expenses to be approximately 4.0% to 6.0% of sales for 1999. Management plans to extend its plastics molding and sensor-based technologies into new markets including neuroradiology, urology, wound care, nephrology, pain management, and critical care. The company is investing heavily to expand its OEM business.
Risks and Contingencies:
- Regulatory Compliance: Operations are subject to FDA regulations (510(k) and PMA) and foreign regulatory approvals. Failure to comply could adversely affect the business.
- Product Liability: While no claims have been experienced, the company maintains $5,000,000 in product liability insurance, which management notes may not be adequate for actual liabilities incurred.
- Competition: Competitors include larger firms with greater financial resources. The company faces risks from alternative treatments (e.g., laser angioplasty, stents, drug therapies) that could render its products obsolete.
- Legal Proceedings: A shareholder derivative lawsuit regarding the formation of Sentir, Inc. was dismissed in September 1998, but the plaintiff has appealed, and the appeal remains pending.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from projections due to market acceptance, regulatory delays, cost increases, and foreign currency fluctuations.
Investor Verification Checklist
- Financial Statements: Verify total revenue, net income, and cash flow figures in the Annual Report to Shareholders (Exhibit 13.1), as these are not explicitly detailed in the 10-K text.
- Legal Status: Monitor the status of the pending appeal regarding the shareholder derivative lawsuit against the CEO and Sentir, Inc.
- Product Adoption: Assess the market acceptance and revenue contribution of the new 1998 product launches (Fountain, Tomcat, Squirt).
- International Exposure: Review the impact of foreign currency fluctuations on the 22% of sales derived from international markets.
- Insurance Adequacy: Evaluate the sufficiency of the $5,000,000 product liability coverage relative to the company's growth and risk profile.